Aegerion Pharmaceuticals (United States)

Recent papers from Aegerion Pharmaceuticals (United States)

1. Multi-omic analysis reveals a key BCAT1 role in mTOR activation by B-cell receptor and TLR9.2025
2. BCAT1 Associates with DNA Repair Proteins KU70 and KU80 and Contributes to Regulate DNA Repair in T-Cell Acute Lymphoblastic Leukemia (T-ALL)International Journal of Molecular Sciences · 2024
3. BCAT1 is a NOTCH1 target and sustains the oncogenic function of NOTCH1Haematologica · 2024
4. BCAT1 affects mitochondrial metabolism independently of leucine transamination in activated human macrophagesJournal of Cell Science · 2020
5. Comorbidities and Survival in Patients With Lipodystrophy: An International Chart Review StudyThe Journal of Clinical Endocrinology & Metabolism · 2019
6. Safety and Efficacy of Lomitapide in Japanese Patients with Homozygous Familial Hypercholesterolemia (HoFH): Results from the AEGR-733-301 Long-Term Extension StudyJournal of Atherosclerosis and Thrombosis · 2018
7. Estimating the prevalence of generalized and partial lipodystrophy: findings and challengesDiabetes Metabolic Syndrome and Obesity · 2017
8. Oral Apolipoprotein A‐I Mimetic D‐4F Lowers HDL‐Inflammatory Index in High‐Risk Patients: A First‐in‐Human Multiple‐Dose, Randomized Controlled TrialThe Medicine Forum · 2017
9. BCAT1 controls metabolic reprogramming in activated human macrophages and is associated with inflammatory diseasesNature Communications · 2017
10. Efficacy and Safety of Lomitapide in Japanese Patients with Homozygous Familial HypercholesterolemiaJournal of Atherosclerosis and Thrombosis · 2017
11. Pharmacokinetics and Pharmacodynamics of Lomitapide in Japanese SubjectsJournal of Atherosclerosis and Thrombosis · 2015
12. LOWER, a registry of lomitapide-treated patients with homozygous familial hypercholesterolemia: Rationale and designJournal of clinical lipidology · 2015
13. The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia – A post-hoc analysis of a Phase 3, single-arm, open-label trialAtherosclerosis · 2015
14. Pharmacokinetic Interactions of the Microsomal Triglyceride Transfer Protein Inhibitor, Lomitapide, with Drugs Commonly Used in the Management of HypercholesterolemiaPharmacotherapy The Journal of Human Pharmacology and Drug Therapy · 2013
15. Pharmacokinetics, pharmacodynamics, and safety of clevidipine after prolonged continuous infusion in subjects with mild to moderate essential hypertensionEuropean Journal of Clinical Pharmacology · 2012
16. Antitumor activity of efrapeptins, alone or in combination with 2-deoxyglucose, in breast cancer in vitro and in vivoCell Stress and Chaperones · 2010
17. Quality of Extemporaneously Compounded Nitroglycerin OintmentDiseases of the Colon & Rectum · 2007